

Joseph Michael Scandura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6953044/publications.pdf>

Version: 2024-02-01

96
papers

3,605
citations

172457

29
h-index

138484

58
g-index

103
all docs

103
docs citations

103
times ranked

6846
citing authors

#	ARTICLE	IF	CITATIONS
1	Excess mortality in younger patients with myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2023, 64, 725-729.	1.3	5
2	Normal life expectancy for polycythemia vera (PV) patients is possible. <i>Leukemia</i> , 2022, 36, 569-572.	7.2	16
3	Defining disease modification in myelofibrosis in the era of targeted therapy. <i>Cancer</i> , 2022, 128, 2420-2432.	4.1	24
4	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. <i>Cancer Discovery</i> , 2022, 12, 2120-2139.	9.4	14
5	Hematopoietic fitness of <i>JAK2V617F</i> myeloproliferative neoplasms is linked to clinical outcome. <i>Blood Advances</i> , 2022, 6, 5477-5481.	5.2	4
6	Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms. <i>European Journal of Haematology</i> , 2021, 106, 250-259.	2.2	7
7	Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. <i>Leukemia</i> , 2021, 35, 2592-2601.	7.2	52
8	Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. <i>Communications Biology</i> , 2021, 4, 785.	4.4	3
9	Reversal of emphysema by restoration of pulmonary endothelial cells. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	37
10	Diffuse Large B Cell Pdx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents. <i>Blood</i> , 2021, 138, 2406-2406.	1.4	1
11	Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for <i>JAK2 V617F</i> Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , 2021, 138, 627-627.	1.4	1
12	Normal Life Expectancy for Polycythemia Vera Patients Is Possible. <i>Blood</i> , 2021, 138, 2575-2575.	1.4	1
13	Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial. <i>Blood</i> , 2021, 138, 141-141.	1.4	16
14	Extracting and classifying diagnosis dates from clinical notes: A case study. <i>Journal of Biomedical Informatics</i> , 2020, 110, 103569.	4.3	9
15	Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model. <i>Journal of Immunology</i> , 2020, 205, 2489-2498.	0.8	13
16	Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. <i>Blood</i> , 2020, 135, 1062-1066.	1.4	19
17	Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. <i>Haematologica</i> , 2020, 105, e221-e224.	3.5	8
18	Megakaryocyte TGF β 1 partitions erythropoiesis into immature progenitor/stem cells and maturing precursors. <i>Blood</i> , 2020, 136, 1044-1054.	1.4	11

#	ARTICLE	IF	CITATIONS
19	Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival. <i>Blood</i> , 2020, 136, 31-32.	1.4	4
20	Somatic mutations and cell identity linked by Genotyping of Transcriptomes. <i>Nature</i> , 2019, 571, 355-360.	27.8	206
21	Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasms Associated Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 1574-1585.	2.8	12
22	Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 466-473.	2.0	4
23	Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival. <i>Blood</i> , 2019, 134, 2942-2942.	1.4	1
24	Recombinant Interferon- β Reduces Thrombotic Events in Patients with Polycythemia Vera. <i>Blood</i> , 2019, 134, 1664-1664.	1.4	1
25	Low-Dose Epo after Tgfr β Blockade Triggers Robust Erythropoiesis and Increased RBC Production. <i>Blood</i> , 2019, 134, 2217-2217.	1.4	0
26	CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. <i>Leukemia and Lymphoma</i> , 2018, 59, 821-828.	1.3	11
27	Lessons Learned in the Development of a Computable Phenotype for Response in Myeloproliferative Neoplasms. , 2018, 2018, 328-331.		3
28	Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, 1308-1316.	3.5	34
29	Myeloproliferative Neoplasm (MPN) Driver Mutations Are Enriched during Hematopoietic Stem Cell Differentiation in Patterns That Correlate with Clinical Phenotype and Treatment Response. <i>Blood</i> , 2018, 132, 4317-4317.	1.4	2
30	Development of an Automated Tool for Assessing Response in Patients with Polycythemia Vera. <i>Blood</i> , 2018, 132, 5462-5462.	1.4	1
31	Ruxolitinib Can Lead to Weight Gain in Patients with Myeloproliferative Neoplasms By Uncoupling Feeding from Central Leptin Signaling Via JAK2/STAT3. <i>Blood</i> , 2018, 132, 4284-4284.	1.4	1
32	High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations. <i>Blood</i> , 2018, 132, 541-541.	1.4	1
33	A Clinical Review of the Co-Occurrence of Myeloproliferative and Lymphoproliferative Neoplasms. <i>Blood</i> , 2018, 132, 4285-4285.	1.4	0
34	Initial Therapy of Polycythemia Vera (PV) with Interferon Alfa (rIFN α) Compared to Hydroxyurea (HU) or Phlebotomy Only (PHL-O) Is Associated with a Lower Risk of Secondary Myelofibrosis. <i>Blood</i> , 2018, 132, 4316-4316.	1.4	0
35	Sox17 drives functional engraftment of endothelium converted from non-vascular cells. <i>Nature Communications</i> , 2017, 8, 13963.	12.8	18
36	Conversion of adult endothelium to immunocompetent haematopoietic stem cells. <i>Nature</i> , 2017, 545, 439-445.	27.8	191

#	ARTICLE	IF	CITATIONS
37	Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells. <i>Cancer Cell</i> , 2017, 31, 110-126.	16.8	108
38	Conversion of adult endothelium into immune-competent haematopoietic stem cells. <i>Experimental Hematology</i> , 2017, 53, S82.	0.4	1
39	Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response. <i>Clinical Cancer Research</i> , 2017, 23, 2673-2680.	7.0	49
40	Abstract 4646: A novel truncated variant of the hematopoietic H β -1 tubulin isotype with implications for stem cell biology. , 2017, , .		0
41	Megakaryocytic TGF β 21 Partitions Hematopoiesis into Amplifying Stem and Progenitor Cells and Maturing Effector Cells. <i>Blood</i> , 2017, 130, 81-81.	1.4	0
42	KRAS and the Reality of Personalized Medicine in Non-Small Cell Lung Cancer. <i>Molecular Medicine</i> , 2016, 22, 380-387.	4.4	14
43	Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 297-303.	0.4	19
44	Step-wise reprogramming of endothelial cells into immune-competent hematopoietic stem cells. <i>Experimental Hematology</i> , 2016, 44, S48-S49.	0.4	0
45	Transplantation of Endothelial Cells to Mitigate Acute and Chronic Radiation Injury to Vital Organs. <i>Radiation Research</i> , 2016, 186, 196-202.	1.5	21
46	A Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S24.	0.4	0
47	Direct Conversion of Adult Endothelial Cells into Immunocompetent Long-Term Engraftable Clinically Scalable Hematopoietic Stem Cells: Pathway to Therapeutic Translation. <i>Blood</i> , 2016, 128, 372-372.	1.4	1
48	Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies. <i>Blood</i> , 2016, 128, 2816-2816.	1.4	0
49	Cutting the brakes on hematopoietic regeneration by blocking TGF β 2 to limit chemotherapy-induced myelosuppression. <i>Molecular and Cellular Oncology</i> , 2015, 2, e978703.	0.7	5
50	An Alternative Retinoic Acid-responsive Stra6 Promoter Regulated in Response to Retinol Deficiency. <i>Journal of Biological Chemistry</i> , 2015, 290, 4356-4366.	3.4	23
51	A phase I trial of a pharmacodynamically-conceived decitabine/thioguanine combination in patients with advanced myeloid malignancies.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18025-e18025.	1.6	0
52	Abstract 5096: ALIB1: a novel, truncated tubulin isotype in AML and stem cells. , 2015, , .		0
53	The Rad50 hook domain regulates DNA damage signaling and tumorigenesis. <i>Genes and Development</i> , 2014, 28, 451-462.	5.9	43
54	Angiocrine Factors Deployed by Tumor Vascular Niche Induce B Cell Lymphoma Invasiveness and Chemoresistance. <i>Cancer Cell</i> , 2014, 25, 350-365.	16.8	203

#	ARTICLE	IF	CITATIONS
55	Activation of the vascular niche supports leukemic progression and resistance to chemotherapy. <i>Experimental Hematology</i> , 2014, 42, 976-986.e3.	0.4	47
56	Reprogramming human endothelial cells to haematopoietic cells requires vascular induction. <i>Nature</i> , 2014, 511, 312-318.	27.8	211
57	Interleukin 2 Receptor- $\hat{\pm}$ (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 1041-1041.	1.4	2
58	Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib. <i>Blood</i> , 2014, 124, 1811-1811.	1.4	3
59	Comprehensive Geriatric Assessment Does Not Predict Overall Survival in Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 3689-3689.	1.4	1
60	Direct Reprogramming of Amniotic Cells into Endothelial Cells. , 2014, , 67-85.		0
61	Phase I study of epigenetic priming using azacitidine prior to neoadjuvant chemotherapy in patients with resectable esophageal and gastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4047-4047.	1.6	0
62	A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies. <i>Blood</i> , 2014, 124, 974-974.	1.4	0
63	RAR $\hat{3}$ is Essential for Retinoic Acid Induced Chromatin Remodeling and Transcriptional Activation in Embryonic Stem Cells. <i>Journal of Cell Science</i> , 2013, 126, 999-1008.	2.0	50
64	Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 2003-2007.	1.3	137
65	Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. <i>Nature Medicine</i> , 2013, 19, 50-56.	30.7	174
66	TGF $\hat{2}$ restores hematopoietic homeostasis after myelosuppressive chemotherapy. <i>Journal of Experimental Medicine</i> , 2013, 210, 623-639.	8.5	73
67	A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1040-1045.	2.0	17
68	Combining Decitabine With Plerixafor Yields a High Response Rate In Newly Diagnosed Older Patients With AML. <i>Blood</i> , 2013, 122, 621-621.	1.4	6
69	Imatinib resistance and microcytic erythrocytosis in a Kit ^{V558I} ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2276-83.	7.1	26
70	Development of a vascular niche platform for expansion of repopulating human cord blood stem and progenitor cells. <i>Blood</i> , 2012, 120, 1344-1347.	1.4	90
71	Are low-intensity induction strategies better for older patients with acute myeloid leukemia?. <i>Leukemia Research</i> , 2012, 36, 407-412.	0.8	8
72	TGF $\hat{2}$ Restores Hematopoietic Homeostasis After Chemotherapy.. <i>Blood</i> , 2012, 120, 2344-2344.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. <i>Blood</i> , 2011, 118, 1472-1480.	1.4	116
74	Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas. <i>Cancer Discovery</i> , 2011, 1, 587-597.	9.4	108
75	Epigenomic Reorganization of the Clustered Hox Genes in Embryonic Stem Cells Induced by Retinoic Acid. <i>Journal of Biological Chemistry</i> , 2011, 286, 3250-3260.	3.4	86
76	DNA Methylation of the First Exon Is Tightly Linked to Transcriptional Silencing. <i>PLoS ONE</i> , 2011, 6, e14524.	2.5	503
77	Abstract 1113: TGF β 2 pathway activation limits hematopoietic recovery from chemotherapy. , 2011, , .		0
78	A Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory leukemia.. <i>Blood</i> , 2010, 116, 1334-1334.	1.4	1
79	Abstract 2548: P57Kip2 restrains the stress response of hematopoietic stem cells and its absence leads to chemotherapy resistance. , 2010, , .		0
80	Abstract 2196: Genome-wide analysis of DNA methylation patterns in formaldehyde-fixed paraffin-embedded (FFPE) human tumor specimens. , 2010, , .		0
81	CDKN1C Modulates the Stress-Response of Hematopoietic Stem Cells Rendering Hematopoiesis Resistant to Chemotherapeutics. <i>Blood</i> , 2010, 116, 3162-3162.	1.4	0
82	Decitabine-Based Salvage Therapy in Adults with Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2063-2063.	1.4	3
83	Evaluation of Alternative, "Low-intensity" Induction Regimens in Elderly Adults with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 2066-2066.	1.4	1
84	Genome-Wide Analysis of DNA Methylation Patterns Reveals Dynamic Epigenetic Regulation of the AML Genome After Decitabine Treatment.. <i>Blood</i> , 2009, 114, 591-591.	1.4	1
85	Epigenetic Priming with Decitabine Prior to Standard Induction Chemotherapy in Less-Than-Favorable Risk Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2009, 114, 3079-3079.	1.4	0
86	Tumor promoting properties of the ETS protein MEF in ovarian cancer. <i>Oncogene</i> , 2007, 26, 4032-4037.	5.9	37
87	Advances in the molecular genetics of acute leukemia. <i>Current Oncology Reports</i> , 2005, 7, 323-332.	4.0	5
88	Transforming growth factor β 2-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15231-15236.	7.1	221
89	Structural integrity and expression of the <i>L3MBTL</i> gene in normal and malignant hematopoietic cells. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 203-213.	2.8	37
90	The Human L(3)MBT Polycomb Group Protein Is a Transcriptional Repressor and Interacts Physically and Functionally with TEL (ETV6). <i>Journal of Biological Chemistry</i> , 2003, 278, 15412-15420.	3.4	102

#	ARTICLE	IF	CITATIONS
91	Transcription factor fusions in acute leukemia: variations on a theme. <i>Oncogene</i> , 2002, 21, 3422-3444.	5.9	97
92	Structural and Functional Characterization of Platelet Receptor-mediated Factor VIII Binding. <i>Journal of Biological Chemistry</i> , 2000, 275, 13071-13081.	3.4	50
93	The Mechanism by Which Heparin Promotes the Inhibition of Coagulation Factor XIa by Protease Nexin-2. <i>Journal of Biological Chemistry</i> , 1997, 272, 26139-26144.	3.4	19
94	Progress Curve Analysis of the Kinetics with Which Blood Coagulation Factor XIa Is Inhibited by Protease Nexin-2. <i>Biochemistry</i> , 1997, 36, 412-420.	2.5	45
95	Factor X Bound to the Surface of Activated Human Platelets Is Preferentially Activated by Platelet-Bound Factor IXa. <i>Biochemistry</i> , 1996, 35, 8903-8913.	2.5	37
96	A Binding Site Expressed on the Surface of Activated Human Platelets Is Shared by Factor X and Prothrombin. <i>Biochemistry</i> , 1996, 35, 8890-8902.	2.5	59